06/02/23 2:00 AMOTC, Nasdaq : EVTCY, EVO Evotec Receives Grant from Open Philanthropy for Discovery of RNA-Targeting Henipavirus Therapeutics$ 1.7 M-GRANT FROM OPEN PHILANTHROPY WILL SUPPORT DEVELOPMENT OF SMALL MOLECULE ANTIVIRALS THAT TARGET VIRAL RNA IN HENIPAVIRUSESEVOTEC LEVERAGES ITS PROPRIETARY SMALL MOLECULE RNA TARGETING PLATFORMHENIPAVIRAL AGENTS ARE PRIORITY PATHOGENS LISTED ON THE WHO'S R&D BLUEPRINT LIST OF EPIDEMICRHEA-AIneutral
05/12/23 6:30 PMOTC, Nasdaq : EVTCY, EVO earningsEvotec publishes Annual Report 2022 and Quarterly Statement for Q1 2023PUBLICATION OF ANNUAL REPORT 2022: "AHEAD OF THE CURVE"QUALITATIVE QUARTERLY STATEMENT FOR THE FIRST QUARTER OF 2023GUIDANCE FOR FY2023 AND MID-TERM GUIDANCE FOR 2025 UNCHANGEDHAMBURG, GERMANY / ACCESSWIRE / May 12, 2023 / Evotec SE (Frankfurt Stock Exchange: Prime Standard, ISIN:RHEA-AIneutral
05/09/23 2:55 PMOTC, Nasdaq : EVTCY, EVO partnershipJust - Evotec Biologics Enters Strategic Biosimilars Partnership with SandozHHAMBURG, GERMANY / ACCESSWIRE / May 9, 2023 / Evotec SE (Frankfurt Stock Exchange: EVT, Prime Standard, ISIN: DE 000 566480 9, WKN 566480; NASDAQ:EVO) announces that Evotec's Seattle-based subsidiary, Just - Evotec Biologics, Inc., has entered a multi-year, long-term tech partnership with SandozRHEA-AIneutral
05/09/23 2:30 PMOTC, Nasdaq : EVTCY, EVO partnershipJust - Evotec Biologics Launches Tech Partnership for Biosimilars Development and Commercial ManufacturingJUST - EVOTEC BIOLOGICS AND SANDOZ JOIN FORCES TO DEVELOP AND MANUFACTURE A DEFINED PORTFOLIO OF BIOSIMILAR MOLECULESJUST - EVOTEC BIOLOGICS TO RECEIVE DOUBLE-DIGIT-MILLION UPFRONT, FUTURE PAYMENTS DEPENDENT ON SUCCESSFUL DEVELOPMENT PROGRESS OF US$ 640 M, ADDITIONAL UNDISCLOSED PAYMENTS DEPENDENTRHEA-AIvery positive
04/11/23 8:30 AMNasdaq : RNXT, EVO managementRenovoRx Appoints Leesa Gentry as Senior Vice President of Clinical OperationsRenovoRx, Inc., a biopharmaceutical company focused on the localized treatment of solid tumors, announced today that Leesa Gentry has joined the Company as Senior Vice President of Clinical Operations. Ms. Gentry, an industry expert in clinical trials management, brings the RenovoRx team valuable leadership experience to further advance studies in cancer...RHEA-AIvery positive
04/10/23 8:15 AMOTC, Nasdaq : EVTCY, EVO Evotec SE Provides Update on Cyber AttackEvotec SE (FFSE:EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) today announced an update on the cyber attack that was detected onRHEA-AIneutral
04/07/23 9:20 AMOTC, Nasdaq : EVTCY, EVO Cyber Attack on EvotecEvotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN:DE 000 566480 9, WKN 566480; NASDAQ:EVO) announces that on 06 April, 2023 a cyber attack occurred on Evotec‘s IT systems. As a result, the systems were shut down proactively and disconnectedRHEA-AIneutral
03/28/23 5:20 AMOTC, Nasdaq : EVTCY, EVO partnershipEvotec and Bristol Myers Squibb Extend and Expand Strategic Neurodegeneration Partnership8-YEAR EXTENSION AND EXPANSION OF ONGOING COLLABORATION TO DEVELOP A BROADENED PROGRAMME PIPELINE IN NEURODEGENERATIVE DISEASES PARTNERSHIP LEVERAGES EVOTEC'S PRECISION MEDICINE PLATFORMS FINANICAL TERMS INCLUDE $ 50 M UPFRONT PAYMENT, PERFORMANCE MILESTONES AND TIERED ROYALTIES ON PRODUCT SALESRHEA-AIvery positive
03/28/23 1:30 AMOTC, Nasdaq : EVTCY, EVO earningsEvotec SE Preliminary Fiscal Year 2022 Results: 'Ahead of the Curve' - Very Strong Performance in a Challenging YearEvotec SE (Frankfurt StockRHEA-AIvery positive
03/24/23 3:00 AMOTC, Nasdaq : EVTCY, EVO Evotec Receives US$ 6.6 m Grant for Drug Discovery in TuberculosisGRANT FROM THE BILL & MELINDA GATES FOUNDATION SUPPORTS EVOTEC'S EFFORTS TO DISCOVER AND DEVELOP DRUG CANDIDATES FOR A UNIVERSAL, SHORTER, SAFER AND SIMPLER TUBERCULOSIS DRUG REGIMEN AS ONE OF ITS PROGRAMMES CONTRIBUTING TO THE UN SUSTAINABLE DEVELOPMENT GOAL 3 "WORLD TUBERCULOSIS DAY", 24 MARCHRHEA-AIvery positive
